World Preview 2019, Outlook to 2024

Fill in the gaps on pharma.

The Japanese-language version of World Preview 2019, Outlook to 2024 is now available here.

The latest annual World Preview 2019, Outlook to 2024 comes at one of the most exciting points in the industry’s development. There is significant optimism around the launch of new technologies and the approval of the first cell and gene therapies, resulting in prescription drug sales being forecast to reach $1.18trn in 2024.

Evaluate’s report examines the other key areas that are expected to drive growth, such as orphan drugs which are expected to contribute $239bn of sales in 2024, or oncology therapies with a similar $236bn forecast.

However, as more new technologies reach the market, drug pricing pressure may continue to intensify and damper the overall sales outlook, especially as patent expiries mean almost $200bn of sales are at risk by 2024.

Download your complimentary copy of the World Preview 2019, Outlook to 2024 below.

Report highlights

  • Worldwide prescription drugs sales predicted to reach $1.18trn in 2024, with a compound annual growth of 6.9%, significantly higher than the 2.3% CAGR between 2010-2018.
  • Pfizer will continue to be the leading prescription drug company in 2024, with projected sales of $51.2bn. However, Takeda (+11% CAGR) and AstraZeneca (+8% CAGR) are forecast to grow the most.
  • In 2018, new molecule approvals from the FDA reached their highest level in over a decade, and within the current pipeline there are another 431 which are expected to be approved.
  • Vertex’s triple combination, VX-659 / VX-445 + tezacaftor + ivacaftor, is anticipated to be the most valuable project in the pharmaceutical industry pipeline with an NPV of close to $20bn

Download 'World Preview 2019, Outlook to 2024'

All done!

All done!

Check your inbox for an email from Vantage to confirm your email address.
We will be in touch shortly to arrange your EvaluatePharma Vision demo.
Download your white paper, “The Importance of Curiosity”, here.
Download your white paper, “Risk and Return in Pharma”, here.

Thanks for requesting World Preview 2019. You can download your copy here

Thanks for your interest in Evaluate


What does the World Preview 2019, Outlook to 2024 cover?

The report highlights trends in prescription drug sales, patent risk, R&D spend, global brand sales and market performance by therapy area across the world’s leading pharmaceutical and biotech companies.

Where does World Preview 2019 source its data from?

The annual report has traditionally sourced all its data from EvaluatePharma. However, for the first time the 2019 report also includes analysis on the risks and rewards of pharma innovation, which features data from new EvaluatePharma Vision.

What is EvaluatePharma Vision?

EvaluatePharma Vision combines our unparalleled consensus forecasts with breakthrough insights on the risk and reward of the R&D landscape. Our clients include all the top 20 global pharma companies, growing biotechs, investment banks, management consultancies, and leading pharmaceutical service providers.

Does Evaluate produce other free industry reports?

Yes – you can find our full range of data-led reports, covering pharma, biotech, medtech and orphan drugs, on our thought leadership page.